SBRT for Organ-Confined Prostate Cancer
A session from the 2016 RSS Webinar Series as presented by:
This course is available from April 7, 2016 through 11:59 p.m. Eastern time on April 7, 2019. In order to earn credit for this course, participants must:
The activity is approximately 1 hour in length.
STATEMENT OF NEED
Prostate cancer remains the most commonly diagnosed cancer, other than skin cancer, in men in the US, and is the second leading cause of cancer-related deaths in American men. The majority of prostate cancers are diagnosed at an early-stage, where treatment options including surgery, brachytherapy, external beam radiation therapy and active surveillance, all result in excellent local control and survival rates. Each of these treatment options have different urinary, bowel and sexual function side effects and treatment choice is often determined by evaluation of the toxicity profiles associated with the treatment.
Stereotactic body radiotherapy (SBRT), the ability to deliver high doses of radiation in a small number of fractions, is a relatively new (less than 10 years follow-up) treatment option for organ-confined prostate cancer, however studies from several institutions have shown excellent local control with minimal urinary, bowel and sexual function toxicities. Radiobiological studies also suggest an advantage of delivering high doses of radiation per fraction to treat prostate cancer. There is growing interest for the use of SBRT for the treatment of organ-confined prostate and a need to educate healthcare professionals on the rationale, growing body of published reports, treatment techniques, clinical outcomes , toxicity and quality of life after SBRT treatment of organ-confined prostate cancer. This webinar presented by Dr. Alan Katz, a leader in the field of prostate SBRT, will be discussing his 9-year experience treating prostate cancer patients with SBRT, including treatment techniques, clinical outcomes, toxicity and quality of life.
This program is designed to meet the needs of radiation oncologists and physicists with interests in the early prostate SBRT.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AMEDCO and the Radiosurgery Society® (RSS). AMEDCO is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
AMEDCO designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
A note on browser incompatibility:
For more help with technical issues please click here.
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed on the RSS website under the title of the course.
Participants using RSS online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the RSS website for that 3 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. The RSS reserves the right to remove a course before the end of its qualification period.
Please contact email@example.com if you have questions.